The Impact of Qualia Gluthathione+ on Blood Glutathione Levels

NCT07221955 | Not Yet Recruiting

• 1 other identifier: QLS-019
• Study Type: interventional
• Target: 54
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, double-blind, placebo-controlled, parallel-group, triple-armed, study evaluating the effects of two distinct Qualia Glutathione+ formulations on Whole Blood Glutathione levels in the blood of healthy adults aged 45-75 years. Approximately 18 participants will be randomized to one of three study arms: Qualia Glutathione+ version 1, Qualia Glutathione+ version 2, or placebo. Each participant will take two or three capsules of their assigned product once daily in the morning, with or without food, over a 20-day period. The primary outcome is the change in blood glutathione levels, assessed via in lab blood collection at baseline and study completion. Secondary endpoints include questionnaires measuring health-related quality of life, fatigue, and cognitive functioning (PROMIS Global Health-10, PROMIS Short Form v1.0 - Fatigue 10a, PROMIS Cognitive Function - Short Form 8a), evaluation of safety and tolerability, and an Overall Experience Questionnaire (Appendices 1, 4-7). All assessments, including electronic questionnaires, are completed remotely without in-person visits.

Conditions

Effects of Qualia Glutathione+ on Blood Glutathione Levels; Glutathione

Outcome Measures

Primary Outcomes (1)

• Total Glutathione levels from baseline to Day 20

  To assess between-group differences in the change in blood Total Glutathione levels from baseline to Day 20 following supplementation with Qualia Glutathione version 1 versus placebo and Qualia Glutathione version 2 versus placebo

  0-20 days

Secondary Outcomes (6)

• between-group differences in blood Total Glutathione levels

  baseline to day 20

• within-group differences in the change in blood Glutathione levels

  baseline to day 20

• Safety and Tolerability survey

  baseline to days 7, 14 and 20

• PROMIS Global Health-10

  baseline to days 7, 14 and 20

• PROMIS Short Form v1.0 - Fatigue 10a

  baseline to days 7, 14 and 20

Study Arms (3)

Qualia Glutathione+ version 1

ACTIVE COMPARATOR

Qualia Glutathione+ version 1 manufactured by Qualia Life Sciences

Dietary Supplement: Qualia Glutathione+ version 1

Qualia Glutathione+ version 2

ACTIVE COMPARATOR

Qualia Glutathione+ version 2 manufactured by Qualia Life Sciences

Dietary Supplement: Qualia Glutathione+ version 2

Placebo

PLACEBO COMPARATOR

Rice flour placebo

Dietary Supplement: Placebo

Interventions

Qualia Glutathione+ version 1 DIETARY_SUPPLEMENT

Qualia Glutathione+ version 1 manufactured by Qualia Life Sciences

Qualia Glutathione+ version 1

Qualia Glutathione+ version 2 DIETARY_SUPPLEMENT

Qualia Glutathione+ version 2 manufactured by Qualia Life Sciences

Qualia Glutathione+ version 2

Placebo DIETARY_SUPPLEMENT

Rice flour

Placebo

Eligibility Criteria

• Age: 45 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provide voluntary, written, informed consent to participate in the study
• Agree to provide a valid cell phone number and are willing to receive communications through text
• Can read and write English
• Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly
• Willing to complete questionnaires, records, and diaries associated with the study.
• Healthy male and female participants aged 45-75 years
• Willing to go to a local blood draw location for a Whole Blood Total Glutathione measurement (baseline and Day 20)
• Willing to avoid starting new or stopping any existing dietary supplements throughout the study

You may not qualify if:

• Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
• Known food intolerances/allergy to any ingredients in the product
• Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
• Having had a significant cardiovascular event in the past 6 months
• Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
• On immunosuppressive therapy
• Adults lacking capacity to consent
• Active Smokers
• Diagnosed Diabetics

Sponsors & Collaborators

• Qualia Life Sciences: lead

Study Sites (1)

Qualia Life Sciences

Carlsbad, California, 92011, United States

Location

Central Study Contacts

William Scuba

CONTACT

855-281-2328; support@qualialife.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 24, 2025
• First Posted: October 29, 2025
• Study Start: December 2, 2025
• Primary Completion: December 22, 2025
• Study Completion: January 25, 2026
• Last Updated: November 14, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)